DCx Biotherapeutics

Executive Summary

DCx Biotherapeutics is a private, preclinical-stage biotechnology company based in San Diego, focused on developing novel antibody-based therapeutics for oncology and autoimmune diseases. Founded in 2020, the company has raised $150 million to advance its pipeline of proprietary antibodies targeting critical immune checkpoints and tumor antigens. DCx's lead programs leverage bispecific antibodies and antibody-drug conjugates (ADCs) designed to enhance tumor killing while minimizing off-target toxicity. In autoimmune indications, the company is developing antibodies that modulate pathogenic immune responses without broad immunosuppression. With a strong scientific foundation and substantial funding, DCx is positioned to initiate first-in-human trials in the near term, though the preclinical stage implies inherent clinical and regulatory risks.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Oncology Program70% success
• Q2 2026Preclinical Data Presentation at Major Conference90% success
• Q4 2026Series C Financing or Partnership Announcement60% success